Summary Levels of the nucleotide pathway enzyme thymidine kinase (TK) were assayed in the mononuclear leukocytes and serum of 70 female patients with breast cancer and 98 male and 77 female non-cancer hospital patients. The total TK levels in both mononuclear leukocytes and serum from patients with breast cancer were significantly higher than in controls. The serum TK levels showed a significant correlation with cancer stage. No such correlation was observed with mononuclear leukocyte TK levels. Serum TK from 20 patients with breast cancer and 19 control patients was further assayed to ascertain the relative contributions of the thymidine kinase isozymes TK1 and TK2 to total TK levels. The increase in serum TK from breast cancer patients appears to be due to an increase in both TKl and TK2 levels.
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The pyrimidine nucleotide salvage pathway enzyme, thymidine kinase (TK), occurs mainly in two forms in human tissue (for review, see Kit, 1976) . TKl is the cytosolar TK and has high activity in dividing cells but is absent in resting cells (Bello, 1974) . This form of the enzyme has therefore high activity in foetal and neoplastic tissue, but low activity in non-growing adult tissue (Gordon et al., 1968; Machovich & Greengard, 1972; Caron & Unsworth, 1978) . The second form of the enzyme, TK2, is of mitochondrial origin, and is present in the mitochondrial matrix. TK2 activity remains relatively constant throughout the cell cycle (Adler & McAuslin, 1974) . The two TK isozymes have different biochemical properties. TKl migrates slowly during polyacrylamide gel electrophoresis while TK2 migrates rapidly (Kit & Leung, 1974; Taylor et al., 1972) . The two forms of TK also differ in terms of pH optima, heat stability, inhibition by dCTP and phosphate donor specificity (Taylor et al., 1972) . Both isozymes utilise ATP efficiently as phosphate donor with CTP resulting in relative decreases in activity of approximately 85-90% for TKI and 7-30% for TK2 (Taylor et al., 1972; Ellims et al., 1981a) .
Total TK (i.e., TKl + TK2) levels have been found to be elevated in the serum of rats bearing transplanted hepatomas (Taylor et al., 1981) . Kreis et al., (1982) found a substantial increase in total TK levels in the plasma of mice with advanced leukaemias and in humans with acute non-lymphocytic leukaemia, chronic myelocytic leukaemia, pancreatic cancer (with metastasis to liver), fibrohistiocytoma, carcinoid syndrome (with metastasis to bone), and prostate cancer (with metastasis to bone). More recently it has been found that there are elevations in serum total TK levels in patients with non-Hodgkin's lymphoma and cancers of bone (metastatic, primary site unknown), squamous cell, prostate, brain and basal cell (O'Neill et al., 1986 (O'Neill et al., ,1987 . The increases in serum total TK activities appear to be largely the result of increased TKI levels (O'Neill et al., 1987) . This is in agreement with the observations of other workers who have found elevated serum TKI levels in patients with adult nonHodgkin's lymphoma (Ellims et al., 1981b; Gronowitz et al., 1983) , acute lymphoblastic and non-lymphoblastic leukaemia as well as chronic myelogenous leukaemia (Hagberg et al., 1984) , childhood acute lymphoblastic leukaemia (Morgan et al., 1985) , Hodgkin's lymphoma (Eriksson et al., 1985) , multiple myeloma (Simonsson et al., 1985) and secondary brain tumours . Mononuclear leukocyte total TK levels have been found to be elevated in cancers of thyroid and bladder (McKenna et al., 1985; O'Neill et al., 1987 (McKenna et al., 1985) . Thymidine kinase assays were based on methods previously described (O'Neill et al., 1986; McKenna et al., 1985) . After (Ellims et al., 1981a) .
Results
The mononuclear leukocyte total TK activities in patients with breast cancer (all female) and female control patients are presented in Figure 1 . The breast cancer patients (n=70) had a mean age of 57.15 years (+ 1.40 s.e.) and a mean mononuclear leukocyte total TK activity of 13.01 + 0.82 pmol dTMP 10-6 cells h-1. This activity was significantly higher (P<0.05) than that found in female control patients (n=77) who had a mean age of 39.92 + 1.97 and a mean mononuclear leukocyte total TK activity of 10.25 + 0.73 pmol dTMP 10-6 cells h-1.
Although the breast cancer patients were significantly older than control patients, it can be seen from Table I Figure 2 . The breast cancer patients has a mean serum total TK activity of 6.2+0.47 pmol dTMP ml-I h-1 which was significantly higher (P<0.001) than that found in control females (3.69 + 0.20).
Neither age nor sex appears to be a significant determinant of serum total TK activity. No significant overall difference was found between the male and female control patients, however in the > 60 age category females were found to have significantly higher (P < 0.05) serum total levels than males (Table III) Table V .
It can be seen that the mean % CTP/ATP TK activity in the breast cancer patients (62.7%) is similar to that found in the control patients (64.2%). This indicates that the proportions of TK1 and TK2 are similar in both groups of patients and the relative increase in serum total TK activity found in breast cancer patients is likely to be due to an increase in serum levels of both forms of TK. (n = 9) (Gronowitz et al., 1983; Eriksson et al., 1985) and between serum TKI levels and prognosis in patients with acute myelogenous leukaemia (Hagberg et al., 1984) , chronic lymphocytic leukaemia (Kallander et al., 1984) and multiple myeloma (Simonsson et al., 1985) . The serum TK activities obtained using CTP instead of ATP as phosphate donor indicate that the increase in serum total TK levels in breast cancer patients over controls is due to an increase in both TKI and TK2 since the % CTP/ATP TK activity does not differ substantially between the two groups. Kreis et al. (1982) suggested that enhanced plasma TK levels in patients and mice with cancer may be a result of the release of TK into the peripheral blood circulation from tumour cells. This is supported by the finding that rapidly proliferating tumour cells in culture release TK into the surrounding medium (Bristow et al., 1988) . The results described in the present communication would also correspond with the tumour cells being the source of the elevated serum TK levels since Sakamoto et al. (1986) has reported that both isozyme forms of TK are elevated in human mammary tumours with TKI showing the greater increase in activity.
The increase in total TK levels in mononuclear leukocytes is unlikely to be related to the increase in serum TK levels. Mononuclear leukocyte TK levels, unlike serum TK, are not correlated with the stage of advancement of the disease. Whatever the underlying mechanisms it would appear that breast cancer is associated with elevated TK levels in serum and mononuclear leukocytes and measurement of the disease. Work is currently underway to ascertain its usefulness as a prognostic indicator.
